-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Equities Analysts Set Expectations for Ironwood Pharmaceuticals, Inc.'s Q4 2022 Earnings (NASDAQ:IRWD)
Equities Analysts Set Expectations for Ironwood Pharmaceuticals, Inc.'s Q4 2022 Earnings (NASDAQ:IRWD)
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) – Analysts at Capital One Financial lowered their Q4 2022 earnings estimates for Ironwood Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 25th. Capital One Financial analyst T. Chiang now expects that the biotechnology company will earn $0.25 per share for the quarter, down from their previous forecast of $0.29. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $1.00 per share.
Get Ironwood Pharmaceuticals alerts:Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. The company had revenue of $108.64 million for the quarter, compared to the consensus estimate of $111.51 million. Ironwood Pharmaceuticals had a return on equity of 30.24% and a net margin of 39.85%.
Separately, StockNews.com cut shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, December 17th.Ironwood Pharmaceuticals Stock Up 1.6 %
NASDAQ IRWD opened at $11.49 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 25.78 and a current ratio of 25.78. The firm has a 50-day simple moving average of $11.88 and a 200 day simple moving average of $11.37. Ironwood Pharmaceuticals has a twelve month low of $9.73 and a twelve month high of $12.95. The stock has a market cap of $1.76 billion, a PE ratio of 12.09 and a beta of 0.96.
Institutional Trading of Ironwood Pharmaceuticals
Several hedge funds have recently modified their holdings of the company. Natixis Advisors L.P. acquired a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter worth approximately $340,000. Ritholtz Wealth Management increased its holdings in shares of Ironwood Pharmaceuticals by 46.8% in the fourth quarter. Ritholtz Wealth Management now owns 71,164 shares of the biotechnology company's stock valued at $882,000 after purchasing an additional 22,692 shares in the last quarter. Maryland State Retirement & Pension System acquired a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter valued at approximately $683,000. Ronald Blue Trust Inc. increased its holdings in shares of Ironwood Pharmaceuticals by 18,584.6% in the fourth quarter. Ronald Blue Trust Inc. now owns 4,858 shares of the biotechnology company's stock valued at $50,000 after purchasing an additional 4,832 shares in the last quarter. Finally, MQS Management LLC increased its holdings in shares of Ironwood Pharmaceuticals by 77.5% in the third quarter. MQS Management LLC now owns 20,729 shares of the biotechnology company's stock valued at $215,000 after purchasing an additional 9,048 shares in the last quarter.
Insiders Place Their Bets
In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 110,962 shares of the firm's stock in a transaction dated Thursday, January 5th. The shares were sold at an average price of $12.07, for a total transaction of $1,339,311.34. Following the completion of the transaction, the chief executive officer now owns 712,440 shares in the company, valued at $8,599,150.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 13.10% of the company's stock.
Ironwood Pharmaceuticals Company Profile
(Get Rating)
Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.
Featured Stories
- Get a free copy of the StockNews.com research report on Ironwood Pharmaceuticals (IRWD)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Ironwood PharmPharmticals,Inc.(納斯達克代碼:IRWD-GET Rating)-第一資本金融的分析師在1月25日星期三發佈給客戶和投資者的一份研究報告中下調了他們對Ironwood製藥2022年第四季度的收益預期。Capital One Financial分析師T.Chiang現在預計,這家生物技術公司本季度每股收益將為0.25美元,低於此前預測的0.29美元。對Ironwood PharmPharmticals目前全年收益的普遍估計為每股1.00美元。
到達鐵木製藥警報:鐵木製藥(納斯達克:IRWD-GET評級)最近一次發佈季度收益報告是在11月3日星期四。這家生物技術公司公佈本季度每股收益(EPS)為0.28美元,比普遍預期的0.27美元高出0.01美元。該公司本季度營收為1.0864億美元,而市場普遍預期為1.1151億美元。Ironwood PharmPharmticals的股本回報率為30.24%,淨利潤率為39.85%。
另外,在12月17日星期六的一份研究報告中,StockNews.com將Ironwood PharmPharmticals的股票評級從“強勢買入”下調至“買入”。鐵木製藥類股上漲1.6%
納斯達克IRWD週五開盤報11.49美元。該公司的負債權益比率為0.67,速動比率為25.78,流動比率為25.78。該公司的50日簡單移動均線切入位為11.88美元,200日簡單移動均線切入位為11.37美元。Ironwood PharmPharmticals的12個月低點為9.73美元,12個月高位為12.95美元。該股市值為17.6億美元,本益比為12.09倍,貝塔係數為0.96。
鐵木製藥的制度性交易
幾家對沖基金最近調整了對該公司的持股。Natixis Advisors L.P.在第四季度收購了Ironwood PharmPharmticals價值約34萬美元的新股份。Ritholtz Wealth Management在第四季度增持了46.8%的Ironwood PharmPharmticals股票。Ritholtz Wealth Management現在持有這家生物技術公司71,164股,價值882,000美元,上個季度又購買了22,692股。馬利蘭州退休和養老金系統在第四季度收購了Ironwood製藥公司的新股份,價值約68.3萬美元。Ronald Blue Trust Inc.在第四季度增持了18,584.6%的Ironwood PharmPharmticals股票。羅納德·布魯信託公司(Ronald Blue Trust Inc.)現在持有這家生物技術公司4,858股股票,價值5萬美元,該公司在上個季度又購買了4,832股。最後,MQS Management LLC在第三季度增持了77.5%的Ironwood PharmPharmticals股票。MQS Management LLC現在持有這家生物技術公司20,729股股票,價值21.5萬美元,上個季度又購買了9,048股。
內部人士下注
在Ironwood PharmPharmticals的其他消息中,首席執行官託馬斯·A·麥考特在日期為1月5日星期四的交易中出售了110,962股公司股票。這些股票的平均價格為12.07美元,總成交額為1,339,311.34美元。交易完成後,首席執行官現在擁有該公司712,440股,價值8,599,150.80美元。這筆交易是在提交給美國證券交易委員會的一份檔案中披露的,該檔案可以通過美國證券交易委員會網站。公司內部人士持有該公司13.10%的股份。
鐵木製藥公司簡介
(獲取評級)
Ironwood PharmPharmticals,Inc.是一家保健公司,專注於胃腸(GI)產品的開發和商業化。它在美國和墨西哥以Linzess的名義銷售利納克肽,在加拿大和歐盟以Constella的名義銷售利納克肽,這是一種鳥苷環化酵素C型激動劑,用於治療患有便祕(IBS-C)或慢性特發性便祕(CIC)的成年人。
專題報道
- 免費獲取StockNews.com關於鐵木製藥的研究報告(IRWD)
- 市場回顧周-1/23-1/27
- 為什麼Lucid在一天內飆升了近100%
- 利用這些鐵路股票實現增長和收入
- ASML預計今年晶片需求回升,提振銷售觀點
- KLA公司:在動盪不安的半市場中站穩腳跟
接受Ironwood PharmPharmticals Daily新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Ironwood PharmPharmticals和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧